Abstract: Compositions and methods for reducing or preventing graft-versus-host disease associated with allogeneic stem cell transplantation are described. A method includes harvesting hematopoietic cells from a patient with an immunologic disorder and harvesting hematopoietic cells from a donor. The harvested hemaptopoietic cells from the patient and the donor are mixed ex vivo for a period of time sufficient to activate lymphocytes within the hematopoietic cells harvested from the donor such that an immune reaction occurs and an activated portion and an unactivated portion is produced. A rhodamine B derivative is then added to the mixture of cells and the mixture is irradiated at a suitable wavelength and intensity for the selective destruction and/or inactivation of the activated portion without substantially affecting the unactivated portion or causing systemic toxicity in said patient. The irradiated cells are then infused into the patient.
Type:
Grant
Filed:
March 29, 2013
Date of Patent:
August 12, 2014
Assignees:
Universite de Montreal, Hopital Maisonneuve-Rosemont
Inventors:
Denis-Claude Roy, Martin Guimond, Nestor Molfino, Luc Villeneuve
Abstract: Compositions and methods for reducing or preventing graft-versus-host disease associated with allogeneic stem cell transplantation are described. A method includes harvesting hematopoietic cells from a patient with an immunologic disorder and harvesting hematopoietic cells from a donor. The harvested hemaptopoietic cells from the patient and the donor are mixed ex vivo for a period of time sufficient to activate lymphocytes within the hematopoietic cells harvested from the donor such that an immune reaction occurs and an activated portion and an unactivated portion is produced. A rhodamine B derivative is then added to the mixture of cells and the mixture is irradiated at a suitable wavelength and intensity for the selective destruction and/or inactivation of the activated portion without substantially affecting the unactivated portion or causing systemic toxicity in said patient. The irradiated cells are then infused into the patient.
Type:
Application
Filed:
March 29, 2013
Publication date:
November 7, 2013
Applicants:
HOPITAL MAISONNEUVE-ROSEMONT, UNIVERSITE DE MONTREAL
Inventors:
UNIVERSITE DE MONTREAL, HOPITAL MAISONNEUVE-ROSEMONT
Abstract: The present invention relates to the use of the photoactivable derivatives for the photodynamic treatment for the selective destruction and/or inactivation of immunologically reactive cells without affecting the normal cells and without causing systemic toxicity for the patient, wherein appropriate intracellular levels of said derivatives are achieved and irradiation of a suitable wavelength and intensity is applied.
Type:
Grant
Filed:
October 21, 2004
Date of Patent:
April 2, 2013
Assignees:
Universite de Montreal, Hopital Maisonneuve-Rosemont
Inventors:
Denis-Claude Roy, Martin Guimond, Nestor Molfino, Luc Villeneuve
Abstract: The present invention relates to the use of the photoactivable derivatives for the photodynamic treatment for the selective destruction and/or inactivation of immunologically reactive cells without affecting the normal cells and without causing systemic toxicity for the patient, wherein appropriate intracellular levels of said derivatives are achieved and irradiation of a suitable wavelength and intensity is applied.
Type:
Application
Filed:
October 21, 2004
Publication date:
April 27, 2006
Applicants:
Universite de Montreal, Hopital Maisonneuve-Rosemont
Inventors:
Denis-Claude Roy, Martin Guimond, Nestor Molfino, Luc Villeneuve